TransCon CNP

Phase 2Small molecule

AAscendis Pharma Growth Disorders A/S

TransCon CNP is one of 8 small molecule programs targeting Achondroplasia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AchondroplasiaCompleted

AchondroplasiaPhase 2

Completed

Competition

Competitive Landscape

9 competitors in Achondroplasia

#DrugCompanyPhaseTrials

Voxzogo

BioMarin Pharmaceutical

Phase 2

2 2

BMN 333

BioMarin Pharmaceutical

Phase 3

6 3

Truseltiq

HHelsinn Healthcare SA

Phase 2

1 4

Yuviwel

Ascendis Pharma

Phase 2

3 5

ABSK061

AAbbisko Therapeutics Co, Ltd

Phase 2

1 6

TYRA-300

TTyra Biosciences, Inc

Phase 2

1 7

Genotropin

EMD Serono

Preclinical

1 8

TransCon CNP

AAscendis Pharma Growth Disorders A/S

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Achondroplasia4 trials

A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With Achondroplasia

Enrolling by invitation·AAscendis Pharma Growth Disorders A/S·Preclinical·NCT05929807·140 enrolled

ACcomplisH China: A Phase 2, Multicenter, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia

Completed·AAscendis Pharma A/S·Phase 2·NCT05246033·24 enrolled

A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period

Completed·AAscendis Pharma Growth Disorders A/S·Preclinical·NCT05598320·84 enrolled

Show 1 more trial

ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period

Completed·AAscendis Pharma A/S·Phase 2·NCT04085523·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TransCon CNP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TransCon CNP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TransCon CNP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascendis Pharma Growth Disorders A/S company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAscendis Pharma Growth Disorders A/S

TransCon CNP

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Achondroplasia4 trials

References

Drug Info

Quick Facts

Related News